Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.57 |
| ▸ | PPARA | Q07869 | 15/20 | 0.57 |
| ▸ | PPARD | Q03181 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL821405 | 0.92 | PPARG (0.59) | PPARGPPARAPPARDKDM4EHRH3 | |
| SCHEMBL3582919 | 0.86 | PPARG (0.43) | PPARGPPARAPPARDLMNA | |
| SCHEMBL31095004 | 0.85 | KDM4E (0.52) | PPARGPPARAPPARDKDM4EHRH3 | |
| SCHEMBL5814674 | 0.84 | KDM4E (0.57) | PPARGPPARAPPARDKDM4EHRH3 | |
| SCHEMBL31095026 | 0.84 | PPARG (0.50) | PPARGPPARAPPARDKDM4EHRH3 | |
| SCHEMBL12469624 | 0.83 | PPARG (0.46) | PPARGPPARAPPARDKDM4E | |
| SCHEMBL15324598 | 0.83 | MEN1 (0.49) | PPARGPPARAPPARDKDM4E | |
| SCHEMBL6964583 | 0.82 | PPARG (0.57) | PPARGPPARA | |
| SCHEMBL6293717 | 0.82 | PPARG (0.50) | PPARGPPARAPPARDLMNA | |
| SCHEMBL14002819 | 0.81 | PPARG (0.69) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100577660-C | N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists used for the treatment of diabetes | HOFFMANN LA ROCHE | 2010-01-06 | — | — | CN | disclosed |
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7446127-B2 | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders | SK HOLDINGS CO, LTD. (KR) | 2008-11-04 | — | — | US | disclosed |
| EP-1567523-B1 | INDOLYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-08-20 | — | — | EP | disclosed |
| CN-100343250-C | Indole derivatives | HOFFMANN LA ROCHE (CH) | 2007-10-17 | — | — | CN | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| CN-1681808-A | N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists useful for the treatment of diabetes | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | CN | disclosed |
| EP-1567523-A1 | INDOLYL DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| EP-1539746-A1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-20050107371-A1 | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2005-05-19 | — | — | US | disclosed |
| US-6890947-B2 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2005-05-10 | — | — | US | disclosed |
| WO-2005021540-A1 | CHROMAN CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | SK CORPORATION (KR) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004048371-A1 | INDOLYL DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
| US-20040106657-A1 | Indolyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-03 | — | — | US | disclosed |
| WO-2004024726-A1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-25 | — | — | WO | disclosed |
| US-20040053979-A1 | Indolyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106657-A1 | Indolyl derivatives | GPR119, IRS1, INSR | PPARG 354/4885PPARA 286/4885PPARD 207/4885 |
| US-20040053979-A1 | Indolyl derivatives | UGT1A8, CYP2C8, UGT1A1 | PPARG 443/4885PPARA 617/4885PPARD 602/4885 |
| US-20050107371-A1 | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders | GPR119, CEL, ACACA | PPARG 44/4885PPARA 105/4885PPARD 83/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | PPARG 65/4885PPARA 24/4885PPARD 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.